Rewalk Robotics (NASDAQ:RWLK) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Rewalk Robotics (NASDAQ:RWLK) from a hold rating to a buy rating in a report published on Monday, February 4th.

Separately, Zacks Investment Research downgraded shares of Rewalk Robotics from a buy rating to a hold rating in a research note on Thursday, October 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $1.56.

Shares of RWLK opened at $0.26 on Monday. The stock has a market capitalization of $19.40 million, a PE ratio of -0.44 and a beta of 1.88. Rewalk Robotics has a fifty-two week low of $0.16 and a fifty-two week high of $1.35. The company has a debt-to-equity ratio of 3.59, a quick ratio of 2.04 and a current ratio of 2.46.

Rewalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings data on Friday, February 8th. The medical device company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.04. Rewalk Robotics had a negative net margin of 331.18% and a negative return on equity of 3,654.32%. The company had revenue of $1.58 million for the quarter.

A hedge fund recently bought a new stake in Rewalk Robotics stock. Geode Capital Management LLC bought a new position in Rewalk Robotics Ltd (NASDAQ:RWLK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 284,311 shares of the medical device company’s stock, valued at approximately $49,000. Geode Capital Management LLC owned about 0.79% of Rewalk Robotics at the end of the most recent quarter. Institutional investors own 2.78% of the company’s stock.

About Rewalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe.

Featured Article: What is a balanced fund?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.